Trial Site Detail
Drug: |
Regorafenib (BAY 73-4506) |
|||
|---|---|---|---|---|
Trial: |
Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Completed |
|||
University of Freiburg - Tumor Biology CenterBreisacher Straße 117 |
Principal Investigator: |
S. Hedbom |
|---|---|
Contact: |
|
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
University of Freiburg - Tumor Biology Center Website: |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.